Koneru Sree N, Staelin Richard, Rawe Ian M
Clinical Research Division, BioElectronics Corporation, Frederick, MD 13905, USA.
Fuqua School of Business, Duke University, Durham, NC 27708, USA.
Pain Manag. 2019 May;9(3):283-296. doi: 10.2217/pmt-2018-0032. Epub 2019 May 29.
The central sensitization inventory (CSI) is a validated, patient-reported questionnaire that quantifies symptoms of hypersensitivity disorders such as chronic pain, for which central sensitization (CS) may be the etiology. To investigate the analgesic effectiveness of ActiPatch and analyze the relationship between baseline CSI scores and demographics of chronic pain sufferers. Upon completing a 7-day ActiPatch trial, baseline CSI scores along with other assessment measures were obtained via e-mail from 174 chronic pain sufferers. CSI scores were positively correlated with gender (higher for women), baseline visual analog scale scores and pain duration. ActiPatch was found to be effective in reducing baseline pain for all subjects by an average of 4.3 visual analog scale points.
中枢敏化量表（CSI）是一份经过验证的、由患者报告的问卷，用于量化超敏反应性疾病（如慢性疼痛）的症状，而中枢敏化（CS）可能是这些疾病的病因。旨在研究ActiPatch的镇痛效果，并分析慢性疼痛患者的基线CSI评分与人口统计学特征之间的关系。在完成为期7天的ActiPatch试验后，通过电子邮件从174名慢性疼痛患者那里获得了基线CSI评分以及其他评估指标。CSI评分与性别（女性更高）、基线视觉模拟量表评分和疼痛持续时间呈正相关。研究发现，ActiPatch对所有受试者的基线疼痛均有减轻作用，平均降低了4.3个视觉模拟量表评分点。
